Global Dextromethorphan Market, By Product Type (Over-the-counter (OTC), Prescription Drug), Age Group (Pediatric, Adult), Dosage Form (Syrup, Tablet, Others), Route of Administration (Oral, Others), End Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others) – Industry Trends and Forecast to 2030.
Dextromethorphan Market Analysis and Size
The global dextromethorphan market is anticipated to grow rapidly during the forecast period. Coughing is a typical sign of the upper and lower respiratory tract infections. Cough is the most prevalent reason for visits to primary care physicians worldwide, according to data published by the National Center for Biotechnology Information in 2014, accounting for roughly 8% of all consultations. According to the same source, the global annual prevalence of cough in the general population is estimated to be between 10% and 33%.
Data Bridge Market Research analyses that the global dextromethorphan market which was USD 487.25 million in 2022, is expected to reach USD 587.31 million by 2030, and is expected to undergo a CAGR of 4.8% during the forecast period of 2023 to 2030. “Over-the-counter (OTC)” dominates the product type segment of the global dextromethorphan market owing to the high demand of this type of products. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Dextromethorphan Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Product Type (Over-the-counter (OTC), Prescription Drug), Age Group (Pediatric, Adult), Dosage Form (Syrup, Tablet, Others), Route of Administration (Oral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd.(Israel), Sanofi (France), Pfizer Inc. (U.S.), GSK plc. (U.K.), Novartis AG (Switzerland), Sun Pharmaceutical Industries Ltd. (India), Zydus Group (India), Cadila Pharmaceutical (India), Aurobindo Pharma (India), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Intas Pharmaceuticals Ltd. (India), Amneal Pharmaceuticals LLC. (U.S.), Cipla Inc. (U.S.), Hikma Pharmaceuticals PLC (U.K.), 3M (U.S.), Bayer AG (Germany), Ipca Laboratories Ltd. (India), Unique Pharmaceuticals Limited (India)
|
|
Market Opportunities
|
|
Market Definition
Dextromethorphan is a cough suppressant. It's sold separately over-the-counter, but it's also found in a lot of over-the-counter and prescription combination drugs. It has an effect on the brain signals that cause cough reflexes. It is a reflex response to the tracheobronchial tree's chemical, mechanical, or inflammatory irritation, which is transmitted reflexively through neurons in the brainstem by sensory neurons in the airways.
Dextromethorphan Market Dynamics
Drivers
- Increasing Prevalence of Cough Related Conditions
Dextromethorphan is commonly used as an over-the-counter cough suppressant. The rising prevalence of respiratory conditions such as the common cold, flu, bronchitis, and allergies has led to an increased demand for cough medications, driving the growth of the global dextromethorphan market.
- Growing Consumer Awareness and Self Medication
With increased access to healthcare information and self-medication practices, consumers are becoming more aware of over-the-counter medications such as Dextromethorphan. As a result, individuals are more likely to seek relief from cough symptoms by purchasing Dextromethorphan-containing products, contributing to market growth.
- Growing Investment for Healthcare Facilities
Surging focus towards improving the condition of healthcare facilities and improving the overall healthcare infrastructure another important factor fostering the growth of the market. Rising number of partnerships and strategic collaborations between the public and private players pertaining to funding and application of new and improved technology is further creating lucrative market opportunities.
Opportunities
- Expansion of the Pharmaceutical Industry
The pharmaceutical industry is experiencing growth due to various factors, including advancements in drug development, increasing investments in research and development, and expanding healthcare infrastructure. This growth directly impacts the global dextromethorphan market as it is widely used in cough and cold medications.
-
Technological Advancements in Drug Delivery Systems
Innovations in drug delivery systems, such as improved formulations, extended-release formulations, and combination products, have enhanced the efficacy and convenience of cough medications containing dextromethorphan. These advancements attract consumers and contribute to market expansion.
Restraints/Challenges
- Rising Competition
The global dextromethorphan market is highly competitive, with numerous companies offering a wide range of products. This can make it challenging for new entrants or smaller companies to gain market share and establish a strong presence.
-
Side Effects and Safety Concerns
Dextromethorphan, like any medication, can have potential side effects or adverse reactions. Safety concerns, especially when used in high doses or in combination with other substances, can impact consumer confidence and create challenges for market growth.
This global dextromethorphan market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global dextromethorphan market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments
- In September 2021, Sun Pharmaceutical Industries Ltd. announced the launch of a novel formulation in cough management - Chericof 12 (Dextromethorphan Hydrobromide 30 mg and Chlorpheniramine Maleate 4 mg) in India. Chericof 12, India's first prescription cough syrup that provides relief for up to 12 hours, is made with Polistirex technology for long-term medication release. Chericof 12 is only for individuals who are six years old or older.
- In 2020, Johnson & Johnson, the pharmaceutical company has developed and marketed various Dextromethorphan-containing products under their brand names, such as Tylenol Cold & Flu and Robitussin. They have focused on product innovation, introducing new formulations and packaging designs to enhance consumer convenience and compliance.
Global Dextromethorphan Market Scope
The global dextromethorphan market is segmented on the basis of product type, age group, dosage form, route of administration, distribution channel and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product Type
- Over-the-counter (OTC)
- Prescription Drug
Age Group
- Pediatric
- Adult
Dosage Form
- Syrup
- Tablet
- Others
Route of Administration
- Oral
- Others
End Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Global Dextromethorphan Market Regional Analysis/Insights
The global dextromethorphan market is analysed and market size insights and trends are provided by country, product type, age group, dosage form, route of administration, distribution channel and end-user as referenced above.
The countries covered in the global dextromethorphan market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the global dextromethorphan market because of the strong base of healthcare facilities, strong presence of major players in the market, and rising number of research activities in this region.
Asia-Pacific is expected to witness significant growth in the global dextromethorphan market during the forecast period of 2023 to 2030 due to the increase in government initiatives to promote awareness, rise in healthcare facilities, growing research activities in the region, availability of massive untapped markets, large population pool, and the growing demand for quality healthcare in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The global dextromethorphan market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for global dextromethorphan market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the global dextromethorphan market. The data is available for historic period 2015-2020.
Competitive Landscape and Global Dextromethorphan Market Share Analysis
The global dextromethorphan market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global dextromethorphan market.
Some of the major players operating in the global dextromethorphan market are:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd.(Israel)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GSK plc. (U.K.)
- Novartis AG (Switzerland)
- Sun Pharmaceutical Industries Ltd. (India)
- Zydus Group (India)
- Cadila (India)
- Aurobindo Pharma (India)
- AstraZeneca (U.K.)
- Johnson & Johnson Private Limited (U.S.)
- Intas Pharmaceuticals Ltd. (India)
- Amneal Pharmaceuticals LLC. (U.S.)
- Cipla Inc. (U.S.)
- Hikma Pharmaceuticals PLC (U.K.)
- 3M (U.S.)
- Bayer AG (Germany)
- Ipca Laboratories Ltd. (India)
- Unique Pharmaceuticals Limited. (India)
- Aceto (U.S.)
SKU-